ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
Dow Jones
38.589,16
-0,15%
Euro vs US Dollar
1,07175
0,00%
Bitcoin
66.138,38
-0,08%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Y mAbs Therapeutics Inc (YMAB)

  7. Y mAbs Therapeutics Inc (YMAB) News

YMAB

Y mAbs Therapeutics (YMAB)

Y mAbs Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:YMAB
DatumZeitQuelleÜberschriftSymbolFirma
14/06/202403h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
14/06/202403h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
14/06/202403h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
13/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
12/06/202401h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
12/06/202401h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
10/06/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
10/06/202422h44Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/06/202413h05GlobeNewswire Inc.Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
05/06/202413h05GlobeNewswire Inc.Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development OfficerNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414h15GlobeNewswire Inc.Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202414h05GlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
01/06/202403h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
24/05/202400h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
21/05/202422h42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
07/05/202422h05GlobeNewswire Inc.Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsNASDAQ:YMABY mAbs Therapeutics Inc
26/04/202413h05GlobeNewswire Inc.Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024NASDAQ:YMABY mAbs Therapeutics Inc
25/04/202422h05GlobeNewswire Inc.Y-mAbs to Present at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
14/03/202414h05GlobeNewswire Inc.Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202423h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202423h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
07/03/202422h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202422h49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202422h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
06/03/202401h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202413h30GlobeNewswire Inc.Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of DirectorsNASDAQ:YMABY mAbs Therapeutics Inc
04/03/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:YMABY mAbs Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:YMAB

Kürzlich von Ihnen besucht

HUOB
SKEBUSDT
Skeb Coin
CSE
EAT
Nutritional High
BIT
I09004
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten